Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Cash from Financing Activities (2021 - 2025)

Historic Cash from Financing Activities for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to $144.8 million.

  • Prime Medicine's Cash from Financing Activities rose 27585.49% to $144.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.0 million, marking a year-over-year decrease of 2301.13%. This contributed to the annual value of $195.9 million for FY2024, which is 2980473.28% up from last year.
  • As of Q3 2025, Prime Medicine's Cash from Financing Activities stood at $144.8 million, which was up 27585.49% from $197000.0 recorded in Q2 2025.
  • Over the past 5 years, Prime Medicine's Cash from Financing Activities peaked at $184.1 million during Q4 2022, and registered a low of -$1.3 million during Q1 2022.
  • In the last 5 years, Prime Medicine's Cash from Financing Activities had a median value of $134500.0 in 2023 and averaged $33.0 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first tumbled by 9989.46% in 2023, then soared by 23126323.53% in 2024.
  • Over the past 5 years, Prime Medicine's Cash from Financing Activities (Quarter) stood at -$1.1 million in 2021, then surged by 17049.63% to $184.1 million in 2022, then plummeted by 99.89% to $194000.0 in 2023, then tumbled by 99.48% to $1000.0 in 2024, then soared by 14475200.0% to $144.8 million in 2025.
  • Its last three reported values are $144.8 million in Q3 2025, $197000.0 for Q2 2025, and $6.0 million during Q1 2025.